Probiotec commences clinical trial

THE ROADHOUSE PHARMACY: Probiotec Limited (ASX: PBP) announced that further to its ongoing research and development program with Griffith University and other research organisations, the company has commenced a clinical trial to investigate the effectiveness of Glycomax Lactoferrin and bovine whey derived Ig rich fraction (Immunoglobulin) for the treatment of atopic dermatitis.

The study will be undertaken in conjunction with Associate Professor Stephen Shumack and Dr Phillip Tong of the St George Dermatology and Skin Cancer Clinic.

The company said it is also undertaking a gene expression study utilising Lactoferrin and Immunoglobulin with Griffith University.

The trial aims to examine the effect of speciality milk proteins (being Lactoferrin and Immunoglobulin) on atopic dermatitis, otherwise known as Eczema.

Eczema is an inflammatory skin condition Probiotec said is estimated to affect between 2 per cent to 10 per cent of adults in Australia and is more prevalent in children.

Ethics approval for this trial has been obtained with recruitment now underway.

The company expects the trial to be completed prior to the end of the 2015 financial year.

Probiotec claimed that should it be successful, this trial would provide a major step forward in the field for the treatment of a condition that currently has no cure.

Website: www.probiotec.com.au